These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 32745637)

  • 1. Methods to evaluate serogroup B meningococcal vaccines: From predictions to real-world evidence.
    Borrow R; Taha MK; Giuliani MM; Pizza M; Banzhoff A; Bekkat-Berkani R
    J Infect; 2020 Dec; 81(6):862-872. PubMed ID: 32745637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic Characterization of Invasive Meningococcal Serogroup B Isolates and Estimation of 4CMenB Vaccine Coverage in Finland.
    Bodini M; Brozzi A; Giuliani M; Nohynek H; Vainio A; Kuusi M; De Paola R; Pizza M; Medini D; Toropainen M; Serino L; Muzzi A
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic characterization and estimated 4CMenB vaccine strain coverage of 284
    Efron A; Brozzi A; Biolchi A; Bodini M; Giuliani M; Guidotti S; Lorenzo F; Moscoloni MA; Muzzi A; Nocita F; Pizza M; Rappuoli R; Tomei S; Vidal G; Vizzotti C; Campos J; Sorhouet Pereira C
    Hum Vaccin Immunother; 2024 Dec; 20(1):2378537. PubMed ID: 39037011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B
    Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D
    mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218
    [No Abstract]   [Full Text] [Related]  

  • 5. High coverage of diverse invasive meningococcal serogroup B strains by the 4-component vaccine 4CMenB in Australia, 2007-2011: Concordant predictions between MATS and genetic MATS.
    Tozer SJ; Smith HV; Whiley DM; Borrow R; Boccadifuoco G; Medini D; Serruto D; Giuliani MM; Stella M; De Paola R; Muzzi A; Pizza M; Sloots TP; Nissen MD
    Hum Vaccin Immunother; 2021 Sep; 17(9):3230-3238. PubMed ID: 33847225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of expanded
    Borrow R; Martinón-Torres F; Abitbol V; Andani A; Preiss S; Muzzi A; Serino L; Sohn WY
    Expert Rev Vaccines; 2023; 22(1):738-748. PubMed ID: 37622470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage.
    Frosi G; Biolchi A; Lo Sapio M; Rigat F; Gilchrist S; Lucidarme J; Findlow J; Borrow R; Pizza M; Giuliani MM; Medini D
    Vaccine; 2013 Oct; 31(43):4968-74. PubMed ID: 23954380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated strain coverage of serogroup B meningococcal vaccines: A retrospective study for disease and carrier strains in Greece (2010-2017).
    Tzanakaki G; Xirogianni A; Tsitsika A; Clark SA; Kesanopoulos K; Bratcher HB; Papandreou A; Rodrigues CMC; Maiden MCJ; Borrow R; Tsolia M
    Vaccine; 2021 Mar; 39(11):1621-1630. PubMed ID: 33597116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction by genetic MATS of 4CMenB vaccine strain coverage of invasive meningococcal serogroup B isolates circulating in Taiwan between 2003 and 2020.
    Muzzi A; Lu M-C; Mori E; Biolchi A; Fu T; Serino L
    mSphere; 2024 Jun; 9(6):e0022024. PubMed ID: 38752729
    [No Abstract]   [Full Text] [Related]  

  • 10. Culture-Confirmed Invasive Meningococcal Disease in Canada, 2010 to 2014: Characterization of Serogroup B
    Tsang RSW; Law DKS; De Paola R; Giuliani M; Stella M; Zhou J; Deng S; Boccadifuoco G; Giuliani MM; Serino L
    mSphere; 2020 Mar; 5(2):. PubMed ID: 32132156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccines against Neisseria meningitidis serogroup B strains - What does genomics reveal on the Portuguese strain's coverage.
    Bettencourt C; Nogueira P; Paulo Gomes J; João Simões M
    Vaccine; 2022 Aug; 40(33):4772-4779. PubMed ID: 35778280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic variability of Polish serogroup B meningococci (2010-2016) including the 4CMenB vaccine component genes.
    Waśko I; Gołębiewska A; Kiedrowska M; Ronkiewicz P; Wróbel-Pawelczyk I; Kuch A; Hong E; Skoczyńska A
    Vaccine; 2020 Feb; 38(8):1943-1952. PubMed ID: 31980191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular characterization of invasive serogroup B Neisseria meningitidis isolates from Spain during 2015-2018: Evolution of the vaccine antigen factor H binding protein (FHbp).
    Abad R; García-Amil C; Navarro C; Martín E; Martín-Díaz A; Vázquez JA
    J Infect; 2021 Apr; 82(4):37-44. PubMed ID: 33610688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates.
    Biolchi A; De Angelis G; Moschioni M; Tomei S; Brunelli B; Giuliani M; Bambini S; Borrow R; Claus H; Gorla MCO; Hong E; Lemos APS; Lucidarme J; Taha MK; Vogel U; Comanducci M; Budroni S; Giuliani MM; Rappuoli R; Pizza M; Boucher P
    Vaccine; 2020 Nov; 38(47):7542-7550. PubMed ID: 33036804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents.
    Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD;
    BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4CMenB journey to the 10-year anniversary and beyond.
    Abitbol V; Martinón-Torres F; Taha MK; Nolan T; Muzzi A; Bambini S; Borrow R; Toneatto D; Serino L; Rappuoli R; Pizza M
    Hum Vaccin Immunother; 2024 Dec; 20(1):2357924. PubMed ID: 38976659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular characterization of invasive
    Sereikaitė E; Plepytė R; Petrutienė A; Stravinskienė D; Kučinskaitė-Kodzė I; Gėgžna V; Ivaškevičienė I; Žvirblienė A; Plečkaitytė M
    Front Cell Infect Microbiol; 2023; 13():1136211. PubMed ID: 36875527
    [No Abstract]   [Full Text] [Related]  

  • 18. MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine.
    Medini D; Stella M; Wassil J
    Vaccine; 2015 May; 33(23):2629-36. PubMed ID: 25882169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular typing of group B Neisseria meningitidis'subcapsular antigens directly on biological samples demonstrates epidemiological congruence between culture-positive and -negative cases: A surveillance study of invasive disease over a 13-year period.
    Lodi L; Moriondo M; Nieddu F; Ricci S; Guiducci S; Lippi F; Canessa C; Calistri E; Citera F; Giovannini M; Indolfi G; Resti M; Azzari C
    J Infect; 2021 Apr; 82(4):28-36. PubMed ID: 33610687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential benefits of using a multicomponent vaccine for prevention of serogroup B meningococcal disease.
    Watson PS; Novy PL; Friedland LR
    Int J Infect Dis; 2019 Aug; 85():22-27. PubMed ID: 31102824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.